Herein, we have demonstrated that a biomarker panel of TJ proteins (OCLN, Claudin-5, and ZO-1) combined with a stroke severity scale, NIHSS, can be a good prediction model to differentiate between IS patients and SMs. This evidence concerns the gene CLDN5 and Stroke.